Antitumoral effects of Pleurotus ostreatus I-Fraction in breast cancer.

FERRONATO, M.J.; POSTEMSKY, P.D.; ALONSO, E.N.; GUEVARA, J.A.; CURINO, A.C.; RAMBURGER, R.; CUESTAS, J.M.; FACCHINETTI, M.M.

Mar del Plata

Congreso; LXIV Reunión Científica Anual de la Sociedad Argentina de Investigación Clínica (SAIC); 2019

Sociedad Argentina de Investigaciones clínicas

Mushrooms are considered as "small pharmaceutical factories" producing hundreds of bioactive compounds, many of which have shown to exert antitumoral activity in different types of cancer. Argentina has a high mushrooms diversity and important scientific-technological development applied to its cultivation. However, the antitumoral phytotherapeutic potential of edible mushrooms cultivated in our country has not yet been considered. In this context, the purpose of the current study is to determine the antitumoral activity in breast cancer of Pleurotus ostreatus I-Fraction, an extract of water-soluble polysaccharides obtained from fruiting body, initially evaluating its potential immuno-independent antitumoral activity. To achieve the proposed objective, we employed a murine mammary adenocarcinoma 4T1 cells line and performed cell viability assays by colorimetric assay with crystal violet, cell cycle analysis by flow cytometry, and wound healing assay. We found that P. Ostreatus I-Fraction at concentration from 2.5 mg/mL and ranging from 1,0 to 2,5 mg/mL decreased the viability of 4T1 cells in a concentration-dependent manner, at 24 hours and 48 hours respectively (p